Contains No CBI 8e

MILES

8EHQ-0993-12265

Miles Inc.
Mobay Road
Pittsburgh, PA 15205-9741
Phone: 412 777-2000

Document Processing Center, TS-790
ATTN: Section 8(e) Coordinator
Office of Toxic Substances
U.S. Environmental Protection Agency
401 M Street, SW
Washington, DC 20460

August 31, 1993

Dear Sir:

On August 27, 1992, the Chemical Manufacturers Association Chlorobenzenes Panel submitted a Notice of Substantial Risk under Section 8(e) of the Toxic Substances Control Act (TSCA). The notice advised EPA of liver effects in male and female mice at the high dose level in a dietary oncogenicity study of 1,2,4-trichlorobenzene (CAS# 120-82-1). This study was being conducted under a TSCA Section 4 Test Rule. On June 9, 1993 the Panel supplemented the earlier notice with a draft histopathology report confirming the liver as a target organ with induction of liver tumors.

As a follow-up to the earlier submissions, attached are the latest reported histological findings (unaudited) which were also sent to the TSCA Section 4 Office in a Six-Month Progress Report on August 21, 1993. These results include degenerative changes to the adrenals, bilateral degeneration of the testes (O/50 controls versus 9/50 high dose) and empty, contracted seminal vesicles. The low and mid-dose groups have not been histopathologically examined in full, so detection of dose-response relationships cannot be made at this time. Furthermore, as noted in the pathologist report, there are questions as to whether the lesions in the adrenal glands, testes and seminal vesticles are a direct consequence of treatment or are secondary to other ill effects and/or stress. Additional histopathology of these organs will be conducted.

In view of the fact that, at this time, a treatment effect cannot be unequivocally ruled out, it is concluded that submitting these latest results as a follow-up to the previous Section 8(e) filings on trichlorobenzene may be appropriate.

If you have any questions, please contact myself or F. J. Rattay, Manager Regulatory Affairs at 412-777-7471.

93 SEP -8 AM 11:00
OTS PROCESSING CENTER

INIT 09/08/93

Sincerely,
Donald W Lamb
D. W. Lamb, Ph.D
Vice President
Product Safety & Regulatory Affairs
412-777-7431

Enclosure
Certified Mail: P 921 654 209
cc: C. R. Stack - CMA File 93-2-14

52 pgs.

CHEMICAL MANUFACTURERS ASSOCIATION

July 30, 1993

To: Chlorobenzenes 1,2,4 TCB Task Group

Re: Histopathology Report on Dietary Carcinogenicity Study in Mice

Hazleton has provided an initial draft pathology report and draft unaudited histopathology summary incidence tables for the 1,2,4-TCB dietary carcinogenicity study in mice. There are three summary incidence tables for: 1) unscheduled deaths; 2) scheduled deaths; and 3) all deaths.

Hazleton is asking for a sponsor decision on additional microscopic examination of tissues. Re: Cover memo on the pathology report. I would ask that you review this information and let me know what you feel should be done. If necessary, I will schedule a conference call to collectively discuss this matter.

A response by August 16 would be appreciated.

Carol R. Stack, Ph.D.
Manager
Chlorobenzenes 1,2,4-TCB Task Group

OTS DOCUMENT RECEIPT OFC.
93 SEP -8 AM 11:00

2501 M Street, NW, Washington, DC 20037 202-887-1100 Panafax 202-887-1237 Telex 89617 (CMA WSH)

HAZLETON
WASHINGTON
9200 LEESBURG PIKE
VIENNA, VA 22182-1699

Telefax: (703) 759-6947
Confirm: (703) 893-5400 x 5264

FACSIMILE TRANSMISSION

TO: Chemical Manufacturers Association

DATE: July 28, 1993

ATTN: Dr. Carol Stack

cc: D. Brusick
R. Squibb
C. Murphy
R. Cardy

FROM: Dr. Michael R. Moore

TOTAL NUMBER OF PAGES BEING TRANSMITTED: 9

SUBJECT: 104-Week Dietary Carcinogenicity Study with 1,2,4-Trichlorobenzene in Mice (HWA Project No. 2603-102; CMA Reference No. CB-28.0-ONC-HAZ)

Per our telephone conversation of July 27, 1993, attached is the INITIAL DRAFT PATHOLOGY REPORT for the referenced study. Incidence Summary Tables of the histopathology findings will be transmitted in subsequent faxes.

As we discussed, it seems the pending decision is whether to a) declare the adrenal glands, testes, and seminal vesicles as target organs, to be microscopically examined in descending dose order, until a no-effect level versus controls becomes apparent; and/or b) determine if any other tissues should also be examined from the Group 3 animals.

With best regards,

Mike

Michael R. Moore, Ph.D., D.A.B.T.
Associate Director, Toxicology

PSO 2603-102
TOX
McKay
Proj. Mgmt.

3

0 0 0 4

2/9

HAZLETON WASHINGTON

HWA 2603-102

PATHOLOGY REPORT

Four groups of B6C3F1/CrlBr/Charles River mice were each exposed to 1,2,4-Trichlorobenzene at one of four dose levels defined as follows: Group 1 - vehicle control (50 males, 50 females), 0 mg/kg/day; Group 2 - low (50 males, 50 females), 150 mg/kg/day; Group 3 - mid (50 males, 50 females), 700 mg/kg/day; Group 4 - high (50 males, 50 females), 3200 mg/kg/day. Exposure was via the diet for a period of approximately 104 weeks, after which all surviving animals were sacrificed for pathologic evaluation. Evaluation of those animals (including any sacrificed in extremis or dying prior to the scheduled sacrifice) is the subject of this report.

Methods

All surviving animals were sacrificed, at the appropriate time, by exsanguination under barbiturate anesthesia, and all were subjected to a necropsy examination. All surviving animals were weighed once prior to the initiation of exposure, weekly during Weeks 1-16, and once every four weeks thereafter, including just prior to necropsy.

Clinical observations were reviewed at necropsy, and all grossly observed abnormalities were entered directly into the computerized data capture system. kidneys, brain (with brainstem), and testes (with epididymides) were weighed from 10 animals/sex/group. Liver (with gallbladder) was weighed from all animals sacrificed on Days 1, 3, and 4 of the terminal sacrifice.

After gross examination, appropriate samples of each of the following organs/tissues were preserved in 10% neutral-buffered formalin:

masses and associated tissues
gross lesions
brain with brainstem
(medulla/pons, cerebellar cortex, and cerebral cortex)
seminal vesicles
ovaries
uterus with vagina and cervix
mammary gland (females only)
skin

4

pituitary
thyroid (with parathyroids)
thymus
trachea
lungs
heart
salivary glands (mandibular)
liver (with gallbladder)
spleen
kidneys
adrenals
pancreas
testes with epididymides
prostate
esophagus
stomach
duodenum, jejunum, ileum
colon, cecum, rectum
urinary bladder
mesenteric lymph node
mandibular lymph node
sciatic nerve
cervical spinal cord
mid-thoracic spinal cord
lumbar spinal cord
femur with bone marrow
skeletal muscle (thigh)
eyes (with Harderian glands)

After fixation, all bony tissues were decalcified prior to processing. Tissues to be examined histologically were embedded in paraffin, sectioned at 5 μ, and stained with hematoxylin and eosin.

As required by the protocol, histologic evaluations were conducted on those tissues listed above from all animals of Groups 1 and 4 sacrificed at the terminal point of the study and from any animals dying or sacrificed in extremis prior to the scheduled sacrifice. Gross lesions were examined from all animals regardless of exposure level. In addition, the liver was identified as a possible target organ during the initial histopathological evaluations and was then, as required by the protocol, examined histologically from all remaining animals. All histologic findings were entered directly into the computerized data capture system. Most nontumor lesions were graded as to relative severity or degree of involvement (1 = minimal, 2 = slight, 3 = moderate, 4 = moderately severe, 5 = severe). The grades are subjective, comparative evaluations, based on morphology alone, and are not intended by themselves to imply any degree of functional impairment.

Gross and Related Findings

Gross findings are summarized in detail in the tables and appendices.

Survival was drastically reduced in males and females of Group 4 compared to other exposure groups. Only 5/50 males and 0/50 females of Group 4 survived to termination, compared to survival rates that ranged from 74 to 90% in all other sex/dose groups (higher survival in males). Most of the deaths occurred as a result of hepatocellular carcinomas, many of which were large and observed grossly.

Mean terminal body weights may have been affected by exposure to 1,2,4-Trichlorobenzene, but interpretation of terminal weight values alone is confounded by the lack of survival at the highest dose level. However, mean body weights were significantly depressed in Group 4 animals of both sexes for the duration of the study, starting with the first week of exposure. In other groups, body weights were inconsistent compared to controls, but were frequently increased over the duration of the study.

Food consumption was less consistently affected, being generally depressed in Group 4 for the first 55 to 60 weeks, but then rebounding to become increased relative to controls for the remainder of the study. This rebound phenomenon is difficult to explain; nevertheless, body weights did not rebound with the increased food consumption, a condition explainable by the severe pathology present in animals of Groups 3 and 4.

Terminal organ weight data were also clouded by high mortality in Group 4 animals; however, a number of observations are important.

Mean terminal liver weights were significantly increased in males of Groups 2, 3, and 4 and females of Groups 2 and 3 (all Group 4 females died prior to termination). This occurred partly as a result of liver tumors (many of them very large) which were present in increased numbers in males and females of Groups 3 and 4 and partly because of another less obvious alteration observed histologically, which will be described later in this report.

Mean terminal testicular weights appear to have been significantly depressed in Group 4 males compared to all other groups. There was no clear histologic correlate, but the histologic data do

suggest an increase in the degree of degenerative changes within the testes of Group 4 animals.

The most commonly described gross abnormalities were masses, enlargements, or irregularities of contour within the liver. Seen mostly in males and females of Group 4 and indicative of an effect of exposure to the test substance, most of these lesions were subsequently shown histologically to be hepatocellular carcinomas. It was common for these neoplasms to be accompanied by grossly noted accumulations of ascitic fluid.

"Lumen, material" was frequently described within the glandular stomach of many terminal-sacrifice animals without relation to dose. This was the result of mice licking their tail after the tip had been amputated for blood collection and not reflective of any lesion of the stomach itself.

Cysts were frequently observed grossly within the ovaries and uterus of female mice without relation to exposure. Both are common, age-related lesions that occur in laboratory mice of this and other strains as a result of endocrine senescence.

"Pale area" was noted in the kidneys of Group 4 animals of both sexes at a higher incidence than any other exposure groups. There was no specific histologic correlate.

Histopathology

Histologic findings are summarized in the tables and appendices.

There was a large (and significant) increase in the incidence of hepatocellular carcinomas in males and females of Groups 3 and 4 compared to the other groups. Hepatocellular carcinomas were present in 100% of examined Group 4 males, 92% of Group 4 females, 54% of Group 3 males, and 56% of Group 3 females. The tumors were mostly large and often multiple, frequently with pulmonary metastases. Architecturally, the carcinomas were heterogeneous, often characterized by some degree of trabeculation.

6/9

Adenomas were also increased in incidence in the same groups (except Group 4 males, in which they were likely overwhelmed by the exten carcinoma development), but were smaller and more circumscribed, with architectural and cytologic variation. Necrosis, often present within neoplasms and in the adjoining parenchyma, was mostly interpreted secondary to the neoplasia.

Also present within liver tissue, and clearly associated dire with 1,2,4-Trichlorobenzene exposure, was enlargement of hepatoc within the centrilobular zone of livers from many males of Groups 3 an including animals with and without concurrent hepatic neopla Hepatocytic cytoplasm within affected areas appeared slightly more d and eosinophilic than normal. This change, when seen, is often associ with increased liver weights.

Other hepatic alterations, including focal necrosis, po inflammation and fibrosis, and regenerative changes were also relate exposure to the test substance, but were likely secondary to or influe by the severe degree of hepatic neoplasia present in these animals.

None of the other observed histologic changes were cle attributable to 1,2,4-Trichlorobenzene exposure.

A number of spontaneous lesions that are normally increase mice of this strain and age were seen less frequently in animals of G 4 as a result of the very high mortality that occurred in both males females at that exposure level. Included in this group of lesions focal mineralization within the thalamic region of the brain, develop of peribronchial/perivascular lymphoid aggregates within the lu lesions of chronic progressive nephropathy, and development of ova cysts and uterine cystic endometrial hyperplasia.

The adrenal glands of aging mice, mostly female, freque exhibited congestion and degenerative changes within the inner cort region, resulting in hemorrhage and necrosis in the more severe cases. addition, many of these glands show varying degrees of hyperplasia of

HAZLETON WASHINGTON

subcapsular spindle-cell population. These changes are all hormonally related to age and sex and are expected in normal mice of this age and strain. They are not restricted entirely to females, but the degenerative changes, especially, are generally much more pronounced in that sex. That pattern was true for this study; however, in males, there was the impression of increased congestion/hemorrhage and degenerative changes within the corticomedullary region of the adrenals in animals of Group 4 compared to control. It is important to consider, however, that many Group 4 males died and were necropsied without exsanguination, and in many of these autolysis within this anatomic area was considerable. It is, therefore, likely that the observed increase in degenerative changes recorded for this area was artifactual rather than any direct effect of exposure to the test substance.

The seminal vesicles of Group 4 males often appeared empty and contracted. Not observed in animals of other exposure groups, this finding is compatible with a toxic effect. It is, however, also compatible with a prolonged cachectic and terminal disease process during which normal secretory activities were decreased or stopped. The same is true for the testes of Group 4 males, in which there was an increase in the observed incidence of degenerative changes within seminiferous tubules.

All other histologic changes were comparably distributed between examined groups and of the types and general frequencies of those usually encountered in normal populations of mice of this strain and age.

Discussion and Conclusions

Dietary exposure of B6C3F1 mice to 1,2,4-Trichlorobenzene for 2 years, or until death intervened, resulted in the induction of liver tumors (mostly hepatocellular carcinomas, but also significant numbers of adenomas) in males and females of Groups 3 and 4. Because liver was shown early in the study to be a target organ, all livers were examined

histologically; thus, the relatively low incidence of liver tumors at the Group 2 level (comparable to control incidences) would suggest that there was no hepatocarcinogenic effect of exposure at that level.

Centrilobular hepatocellular hypertrophy was also seen in males of Groups 3 and 4 as a direct result of exposure to the test substance.

Group 4 survival was very poor. All females and all but five males of that group died or were sacrificed in extremis prior to the study's termination, and the pattern of early death became evident quite early - at approximately 65 to 70 weeks into the study for both sexes - and progressed at a rapid rate for the remainder of the study. Comprehensive histopathologic evaluations were performed routinely only on animals of Groups 1 and 4. Tissues other than liver from animals of Groups 2 and 3 (in which survival was excellent) were not examined histologically except from the relatively few animals dying early or unless grossly abnormal; consequently, most of the tissues examined from animals exposed to the test substance were from animals that died early. Except for liver, then, there were relatively few tissues of any kind examined from animals exposed to the test substance for the entire 104 week exposure period.

This is important because in the case of certain lesions, such as those described in the adrenal glands, testes, and seminal vesicles, the relationships to compound exposure are not clearly definable. While those described lesions are of the kinds that might be the result of toxic insult, they are also nonspecific in nature and can be affected profoundly by prolonged severe disease as was seen in animals of Group 4 of this study. It is not possible, from available data, to state unequivocally which is the true situation. Examination of these tissues from animals of Groups 2 and 3 might help to clarify this issue.

9/9

HAZLETON WASHINGTON

Pathologist:

Richard H. Cardy, D.V.M., D.A.B.T.,
Diplomate, American College of Veterinary Pathologists
Department of Pathology

26 July 93
Date

11

HAZLETON
WASHINGTON
9200 LEESBURG PIKE
VIENNA, VA 22182-1699

Telefax: (703) 759-6947
Confirm: (703) 893-5400 x 5264

FACSIMILE TRANSMISSION

TO: Chemical Manufacturers Association

DATE: July 28, 1993

ATTN: Dr. Carol Stack

cc: D. Brusick
R. Squibb
C. Murphy
R. Cardy

FROM: Dr. Michael R. Moore

TOTAL NUMBER OF PAGES BEING TRANSMITTED: 14

SUBJECT: 104-Week Dietary Carcinogenicity Study with 1,2,4-Trichlorobenzene in Mice (HWA Project No. 2603-102; CMA Reference No. CB-28.0-ONC-HAZ)

Per our telephone conversation of July 27, 1993, attached is UNAUDITED DRAFT HISTOPATHOLOGY SUMMARY INCIDENCE TABLE FOR UNSCHEDULED DEATHS (Death = Unsched) for the referenced study. Since almost all of the high-dose (Group 4) mice were unscheduled deaths, the incidence of histopathology findings for the high-dose versus controls is most readily apparent in the attached table.

With best regards,

Mike

Michael R. Moore, Ph.D., D.A.B.T.
Associate Director, Toxicology

PSO/2603-102
TOX
McKay
Proj. Mgmt.

12

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	5	7	9	45	11	13	8	50
** TOP OF LIST **									
TESTIS (TE)	NUMBER EXAMINED:	5	7	9	45	0	0	0	0
	NOT REMARKABLE:	5	7	7	36	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--DEGENERATION, UNILATERAL		0	0	1	1	0	0	0	0
--DEGENERATION, BILATERAL		0	0	0	8	0	0	0	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	5	7	9	44	11	12	8	50
	NOT REMARKABLE:	4	5	3	29	7	9	5	37
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--MINERALIZATION, FOCAL, THALAMUS		1	2	5	15	4	2	2	13
--HEMORRHAGE, FOCAL		0	0	0	0	0	0	1	0
--MALACIA, FOCAL		0	0	0	0	0	1	0	0
--GLIOSIS, FOCAL		0	0	0	0	0	1	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	5	7	9	44	11	12	8	50
	NOT REMARKABLE:	5	7	8	44	11	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	5	7	9	44	11	12	8	50
	NOT REMARKABLE:	5	7	8	44	11	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	5	7	8	44	11	12	8	50
	NOT REMARKABLE:	5	7	7	44	11	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
PITUITARY (PI)	NUMBER EXAMINED:	5	5	7	38	10	12	8	46
	NOT REMARKABLE:	5	5	7	38	9	12	8	46
--B-ADENOMA		0	0	0	0	1	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		5	7	9	45	11	13	8	50
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	4	7	9	44	11	13	8	50
	NOT REMARKABLE:	0	0	0	7	0	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	3	0	1	1	1	0
--B-ADENOMA		0	1	0	0	0	0	0	0
--HYPERPLASIA, SUBCAPSULAR CELL		3	7	8	19	11	13	7	44
--DEGENERATION/NECROSIS, CORTICOMEDULLARY JUNCTION		2	0	1	20	10	9	4	27
--CONGESTION/HEMORRHAGE, CORTICOMEDULLARY JUNCTION		2	0	0	20	2	2	4	25
--NECROSIS, UNILATERAL		0	0	0	1	0	0	0	0
--NECROSIS, BILATERAL		0	0	0	0	0	1	0	0
--HYPERTROPHY, FOCAL		0	1	0	0	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	4	7	9	42	11	13	8	50
	NOT REMARKABLE:	4	7	9	42	11	13	8	50
THYROID (TY)	NUMBER EXAMINED:	4	7	8	43	11	13	8	50
	NOT REMARKABLE:	4	7	8	42	11	13	8	49
--M-"C" CELL CARCINOMA		0	0	0	1	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
PARATHYROID (PT)	NUMBER EXAMINED:	3	7	9	35	10	10	8	46
	NOT REMARKABLE:	3	7	8	35	10	9	7	45
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--CYST(S)		0	0	1	0	0	1	1	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	5	7	9	45	11	12	8	50
	NOT REMARKABLE:	5	7	9	45	10	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		5	7	9	45	11	13	8	50
TRACHEA (TR)	NUMBER EXAMINED:	5	7	9	44	11	12	8	50
	NOT REMARKABLE:	5	7	9	44	11	12	8	50
LUNG (LU)	NUMBER EXAMINED:	5	7	9	45	11	13	8	50
	NOT REMARKABLE:	1	2	2	12	0	1	0	9
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	2	0	4	4	2	0
--B-ALVEOLAR/BRONCHIOLAR ADENOMA		1	0	1	2	0	0	0	1
--M-ALVEOLAR/BRONCHIOLAR CARCINOMA		1	0	1	0	0	0	0	0
--N-HEPATOCELLULAR CARCINOMA, METASTATIC		0	0	0	9	0	0	0	8
--N-KUPFFER CELL SARCOMA		0	0	0	1	0	0	1	0
--N-SARCOMA, METASTATIC, PRIMARY UNKNOWN		0	0	0	1	0	0	0	0
--N-FIBROSARCOMA, METASTATIC		0	0	1	0	0	0	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		1	4	4	15	7	8	6	23
--CONGESTION/HEMORRHAGE, AGONAL		1	1	1	22	2	1	2	18
--FOAM-CELL FOCUS(I)		1	0	0	2	0	0	0	4
--INFLAMMATION, CHRONIC, FOCAL		0	0	1	1	1	0	1	1
--INFLAMMATION, SUBACUTE, TUMOR ASSOCIATED		1	0	0	0	0	0	0	0
--HYPERPLASIA, HILAR LYMPH NODE		0	0	0	0	0	0	0	1
HEART (HT)	NUMBER EXAMINED:	5	7	9	45	11	13	8	50
	NOT REMARKABLE:	5	7	8	42	10	10	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--FIBROSIS, MYOCARDIUM		0	0	0	2	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--DEGENERATION, MYOCARDIUM		0	0	0	1	0	2	1	1
--INFLAMMATION, CHRONIC, FOCAL		0	0	0	0	0	1	0	0
LIVER (LI)	NUMBER EXAMINED:	4	7	9	45	11	13	8	50
	NOT REMARKABLE:	2	2	0	0	6	5	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	2	4	0	3	5	3	0
--B-HEPATOCELLULAR ADENOMA		0	0	2	2	0	0	2	8

** CONTINUED ON NEXT PAGE **

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	5	7	9	45	11	13	8	50
** FROM PREVIOUS PAGE **									
LIVER (LI)	NUMBER EXAMINED:	4	7	9	45	11	13	8	50
	NOT REMARKABLE:	2	2	0	0	6	5	0	0
--M-HEPATOCELLULAR CARCINOMA		1	2	5	45	0	0	5	46
--M-KUPFFER CELL SARCOMA		0	0	0	1	0	0	1	0
--M-HEMANGIOSARCOMA		1	0	0	0	1	0	0	0
--HEPATOCYTOMEGALY, CENTRILOBULAR		0	0	2	20	0	0	0	8
--INFLAMMATION, CHRONIC, FOCAL		0	1	2	1	0	0	1	2
--FIBROSIS, PORTAL		0	0	0	2	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE, PORTAL		0	0	0	4	0	0	1	2
--NECROSIS, FOCAL		0	0	2	3	0	1	2	7
--NECROSIS, SINGLE CELL		0	0	0	1	0	0	0	0
--HYPERPLASIA, OVAL CELL		0	0	0	1	0	0	0	0
--HYPERPLASIA, REGENERATIVE		0	0	0	2	0	0	0	0
--HYPERPLASIA, KUPFFER CELL, FOCAL		0	0	0	0	1	0	0	0
--LIPOIDOSIS, NONZONAL		0	0	0	3	0	0	0	0
--LIPOIDOSIS, FOCAL		0	0	0	0	0	1	0	0
--CELLULAR ALTERATION, EOSINOPHILIC		0	0	0	0	0	0	1	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		0	0	0	0	0	1	0	0
--HEMATOCYST, TUMOR ASSOCIATED		0	0	0	0	0	0	1	8
--INFARCTED NODULE		0	0	0	2	1	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--DEGENERATION, CYSTIC		0	1	0	0	0	0	0	0
GALLBLADDER (GB)	NUMBER EXAMINED:	0	3	4	6	4	7	2	12
	NOT REMARKABLE:	0	3	4	5	4	7	2	12
--INSPISSATED, MINERALIZED BILE		0	0	0	1	0	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	4	7	9	44	11	13	8	48
	NOT REMARKABLE:	1	1	1	29	7	9	3	33
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	1	2	1	0
--M-MALIGNANT TUBULE CELL CARCINOMA		0	0	0	0	1	0	0	0
--NEPHROPATHY, CHRONIC PROGRESSIVE		0	2	4	4	0	2	3	6

** CONTINUED ON NEXT PAGE **

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

		--- NUMBER-OF-ANIMALS-AFFECTED ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION	NUMBER:	5	7	9	45	11	13	8	50
** FROM PREVIOUS PAGE **									
KIDNEY (KD)	NUMBER EXAMINED:	4	7	9	44	11	13	8	48
	NOT REMARKABLE:	1	1	1	39	7	9	3	33
--TUBULE, MINERALIZATION		3	3	2	8	1	0	2	5
--TUBULE CELLS, PROTEIN RESORPTION DROPLETS		0	1	1	0	1	0	0	0
--HYPERPLASIA, TUBULAR EPITHELIUM		0	0	0	1	0	0	0	0
--PYELONEPHRITIS		0	2	1	1	0	0	0	0
--AMYLOIDOSIS		0	0	0	1	1	0	0	1
--PIGMENT, PROXIMAL TUBULES		0	0	0	2	0	0	1	4
--PELVIS, DILATATION		0	0	0	0	0	0	0	1
--PELVIS, CALCULUS		0	0	0	0	0	0	1	0
--CYST		1	0	1	1	0	0	0	0
--METAPLASIA, OSSEOUS		0	0	0	0	0	0	0	1
--MINERALIZATION, CAPSULE		0	0	0	1	0	0	0	0
--MAST CELL INFILTRATE		0	1	0	0	0	0	0	0
SPLEEN (SP)	NUMBER EXAMINED:	4	7	9	43	11	13	7	48
	NOT REMARKABLE:	2	3	5	42	5	6	5	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	2	3	0	2	6	2	0
--M-HEMANGIOSARCOMA		1	0	0	0	0	0	0	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		0	1	1	1	3	1	0	0
--PIGMENT, INCREASED		0	1	0	0	1	0	0	0
--CONGESTION/HEMORRHAGE		1	0	0	0	0	0	0	0
--HYPERPLASIA, LYMPHOID		0	0	0	0	1	0	0	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	3	7	8	43	8	11	7	49
	NOT REMARKABLE:	3	6	6	42	7	10	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--HYPERKERATOSIS		0	0	1	0	0	1	0	1
--HEMORRHAGE, MUSCULARIS		0	0	0	1	0	0	0	0
--MAST CELL INFILTRATE		0	1	0	0	0	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		5	7	9	45	11	13	8	50
STOMACH, GL (ST)	NUMBER EXAMINED:	3	6	8	42	8	11	7	49
	NOT REMARKABLE:	3	5	5	41	5	10	7	47
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	2	0	0	0
--ULCER		0	0	1	1	1	0	0	1
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--EROSION		0	1	0	0	1	1	0	0
DUODENUM (DU)	NUMBER EXAMINED:	2	5	5	20	6	6	5	28
	NOT REMARKABLE:	2	5	5	20	4	6	5	27
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--M-CARCINOMA		0	0	0	0	1	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
JEJUNUM (JE)	NUMBER EXAMINED:	2	6	5	13	5	6	4	22
	NOT REMARKABLE:	2	6	5	13	5	6	4	21
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
ILEUM (IL)	NUMBER EXAMINED:	1	6	5	17	5	5	5	20
	NOT REMARKABLE:	1	6	5	17	5	5	5	20
PANCREAS (PA)	NUMBER EXAMINED:	4	7	8	38	10	9	7	48
	NOT REMARKABLE:	3	7	5	38	7	8	7	47
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	3	0	2	1	0	0
--CYTOPLASMIC CHANGE, EOSINOPHILIC		1	0	0	0	0	0	0	0
--CYSTIC DUCT(S)		0	0	0	0	1	0	0	1
CECUM (CE)	NUMBER EXAMINED:	3	4	7	24	5	6	5	25
	NOT REMARKABLE:	3	4	5	24	4	6	5	25
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	1	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	5	7	9	45	11	13	8	50
COLON (CO)	NUMBER EXAMINED:	3	5	6	35	9	11	7	42
	NOT REMARKABLE:	3	5	6	35	9	11	7	42
RECTUM (RE)	NUMBER EXAMINED:	4	6	8	35	9	10	7	43
	NOT REMARKABLE:	4	5	8	35	9	10	7	43
--BLOOD FILLED		0	1	0	0	0	0	0	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	3	5	8	31	8	9	8	45
	NOT REMARKABLE:	2	3	2	21	5	4	4	31
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	4	0	3	5	1	0
--M-HEMANGIOSARCOMA		0	0	0	2	0	0	0	1
--CONGESTION/HEMORRHAGE		0	1	2	8	1	0	3	13
EPIDIDYMIS (EP)	NUMBER EXAMINED:	4	7	9	44	0	0	0	0
	NOT REMARKABLE:	4	7	6	43	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	0	0	0	0
--M-SCHWANNOMA		0	0	1	0	0	0	0	0
--HYPOSPERMIA		0	0	0	1	0	0	0	0
PROSTATE (PR)	NUMBER EXAMINED:	5	7	9	38	0	0	0	0
	NOT REMARKABLE:	4	7	6	37	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	2	0	0	0	0	0
--ATROPHY		0	0	0	1	0	0	0	0
--INFLAMMATION, SUBACUTE		0	0	1	0	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	3	6	9	40	0	0	0	0
	NOT REMARKABLE:	3	6	6	18	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	0	0	0	0
--DECREASED SECRETION, BILATERAL		0	0	0	22	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		5	7	9	45	11	13	8	50
** FROM PREVIOUS PAGE **									
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	3	6	9	40	0	0	0	0
	NOT REMARKABLE:	3	6	6	18	0	0	0	0
--DISTENDED		0	0	1	0	0	0	0	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	11	12	8	45
	NOT REMARKABLE:	0	0	0	0	2	5	3	13
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	2	1	1	0
--B-TERATOMA		0	0	0	0	0	1	0	0
--M-MALIGNANT GRANULOSA/THECA CELL TUMOR		0	0	0	0	0	0	1	1
--M-HEMANGIOSARCOMA		0	0	0	0	0	1	0	0
--N-HEPATOCELLULAR CARCINOMA, METASTATIC		0	0	0	0	0	0	0	1
--ATROPHY		0	0	0	0	5	2	3	28
--BURSA, CYST		0	0	0	0	0	0	0	1
--CYST(S)		0	0	0	0	3	0	2	4
--HEMATOCYST		0	0	0	0	2	3	0	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	9	12	8	49
	NOT REMARKABLE:	0	0	0	0	1	1	2	41
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--B-HEMANGIOMA		0	0	0	0	0	1	0	0
--M-LEIOMYOSARCOMA		0	0	0	0	0	1	0	0
--HYPERPLASIA, CYSTIC ENDOMETRIAL		0	0	0	0	8	11	6	3
--DILATATION		0	0	0	0	0	0	0	4
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	11	11	5	48
	NOT REMARKABLE:	0	0	0	0	8	11	5	46
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	3	0	0	0
--ENDOMETRIAL CYST(S)		0	0	0	0	0	0	0	2

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	5	7	9	45	11	13	8	50
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	11	11	7	48
	NOT REMARKABLE:	0	0	0	0	10	11	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	4	7	9	32	9	9	6	44
	NOT REMARKABLE:	4	6	6	32	7	9	6	42
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	2	0	0	0
--B-SCHWANNOMA		0	0	0	0	0	0	0	2
--INFLAMMATION, SUPPURATIVE		0	0	1	0	0	0	0	0
--INFLAMMATION, SUBACUTE		0	1	0	0	0	0	0	0
--HYPERPLASIA, EPITHELIAL		0	1	0	0	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	4	7	9	44	11	13	8	50
	NOT REMARKABLE:	4	7	7	44	8	11	8	49
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	2	2	0	0
--AMYLOIDOSIS		0	0	1	0	0	0	0	1
--HYPERPLASIA, LYMPHOID		0	0	0	0	1	0	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	5	5	7	40	11	12	8	44
	NOT REMARKABLE:	4	4	6	39	9	9	7	43
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	1	0	2	3	1	1
--CONGESTION/HEMORRHAGE		0	0	0	1	0	0	0	0
EYE (EY)	NUMBER EXAMINED:	2	7	8	36	9	8	6	39
	NOT REMARKABLE:	2	7	7	35	8	8	6	39
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--CATARACT		0	0	0	1	0	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		5	7	9	45	11	13	8	50
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	5	7	9	43	11	13	8	50
	NOT REMARKABLE:	5	6	7	43	11	11	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--B-ADENOMA		0	1	0	0	0	0	0	0
--HYPERPLASIA, FOCAL		0	0	1	0	0	1	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	1	0	0
THYMUS (TH)	NUMBER EXAMINED:	5	5	9	21	8	9	5	29
	NOT REMARKABLE:	4	5	5	21	6	5	4	29
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	4	0	2	4	1	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	5	7	9	45	11	13	8	50
	NOT REMARKABLE:	5	7	6	42	10	12	8	49
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--ATROPHY		0	0	0	2	0	0	0	0
--DEGENERATION		0	0	2	1	0	0	0	1
--LYMPHOCYTIC INFILTRATE		0	0	0	0	0	1	0	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	5	6	9	45	11	12	8	50
	NOT REMARKABLE:	5	4	3	27	6	6	4	28
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--DEGENERATION		0	2	5	18	5	6	4	22
SKIN (SK)	NUMBER EXAMINED:	5	7	9	45	11	12	8	50
	NOT REMARKABLE:	5	6	8	35	10	12	7	41
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--B-TRICHOEPITHELIOMA		0	0	0	0	0	0	1	0
--EDEMA		0	1	0	10	0	0	0	9

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	5	7	9	45	11	13	8	50
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	8	13	7	37
	NOT REMARKABLE:	0	0	0	0	7	9	7	37
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	1	0	0
--DILATATION, DUCT(S)		0	0	0	0	0	2	0	0
--LACTATION		0	0	0	0	0	1	0	0
--HYPERPLASIA, LOBULAR		0	0	0	0	1	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	4	6	9	45	10	13	7	49
	NOT REMARKABLE:	4	5	7	45	7	10	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	1	2	0	0	1	0	1
--HYPERPLASIA, GRANULOCYTIC		0	0	0	0	0	1	0	0
--FIBROOSSEOUS CHANGE		0	0	0	0	3	1	0	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	5	7	9	45	11	13	8	50
	NOT REMARKABLE:	5	7	8	45	11	13	8	50
--FIBROUS OSTEODYSTROPHY		0	0	1	0	0	0	0	0
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	5	7	9	45	11	13	8	50
	NOT REMARKABLE:	4	4	5	45	7	7	6	48
--M-MALIGNANT LYMPHOMA, MIXED		0	3	2	0	1	1	0	0
--M-MALIGNANT LYMPHOMA, LYMPHOCYTIC		0	0	1	0	2	2	0	1
--M-MALIGNANT LYMPHOMA, HISTIOCYTIC		0	0	1	0	0	0	1	1
--M-MALIGNANT LYMPHOMA, UNDIFFERENTIATED		0	0	0	0	0	1	1	0
--M-AUTOLYSED NEOPLASM		1	0	0	0	1	2	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	1	2	1	9	2	7	1	4
	NOT REMARKABLE:	1	0	1	5	2	5	1	2
--EDEMA		0	1	0	3	0	0	0	2
--ATROPHY		0	0	0	2	0	0	0	1
--ACANTHOSIS, FOCAL		0	0	0	0	0	1	0	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	5	7	9	45	11	13	8	50
** FROM PREVIOUS PAGE **									
SKIN, OTHER (SS)	NUMBER EXAMINED:	1	2	1	9	2	7	1	4
	NOT REMARKABLE:	1	0	1	5	2	5	1	2
--INFLAMMATION, GRANULOMATOUS, TAIL		0	0	0	1	0	0	0	0
--INFLAMMATION, SUBACUTE, FOOT		0	1	0	0	0	1	0	0
--ULCER, TAIL		0	0	0	1	0	0	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	1	0	1	0	1	1	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	1	0	1	0	1	0
--M-LEIOMYOSARCOMA		1	0	0	0	0	0	0	0
--M-SARCOMA, UNDIFFERENTIATED		0	0	0	0	0	1	0	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	0	0	0	2	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--CYSTIC DUCT(S)		0	0	0	2	0	0	0	0
LN, OTHER(S) (LN)	NUMBER EXAMINED:	1	1	0	0	0	3	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	1	0	0	0	3	1	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	0	1	0	1	2	1	0	1
	NOT REMARKABLE:	0	1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--M-MYXOSARCOMA		0	0	0	0	0	1	0	0
--FAT NECROSIS		0	0	0	0	1	0	0	1
--HEMORRHAGE		0	0	0	1	0	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=UNSCHED;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		5	7	9	45	11	13	8	50
PENIS (PE)	NUMBER EXAMINED:	0	1	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--INFLAMMATION, NECROTIZING/SUPPURATIVE, PREPUCE		0	1	0	0	0	0	0	0
--INFLAMMATION, NECROTIZING/SUPPURATIVE		0	1	0	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0

** END OF LIST **

HAZLETON
WASHINGTON
9200 LEESBURG PIKE
VIENNA, VA 22182-1699

Telefax: (703) 759-6947
Confirm: (703) 893-5400 x 5264

FACSIMILE TRANSMISSION

TO: Chemical Manufacturers Association

DATE: July 28, 1993

ATTN: Dr. Carol Stack

cc: D. Brusick
R. Squibb
C. Murphy
R. Cardy

FROM: Dr. Michael R. Moore

TOTAL NUMBER OF PAGES BEING TRANSMITTED: 12

SUBJECT: 104-Week Dietary Carcinogenicity Study with 1,2,4-Trichlorobenzene in Mice (HWA Project No. 2603-102; CMA Reference No. CB-28.0-ONC-HAZ)

Per our telephone conversation of July 27, 1993, attached is UNAUDITED DRAFT HISTOPATHOLOGY SUMMARY INCIDENCE TABLE FOR SCHEDULED DEATHS (Death = T); or rather animals killed at study termination per protocol design.

Basically, the attached table indicates the incidence of lesions in the control group (the majority of which survived to study termination), and in the few high-dose animals that survived to study termination, as well as any gross lesions that were detected in the low- and mid-dose groups (Groups 2 and 3) in animals killed at study termination.

With best regards,

Mike

Michael R. Moore, Ph.D., D.A.B.T.
Associate Director, Toxicology

PSO/2603-102
TOX
Bassett
Proj. Mgmt.

26

0 0 2 7

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
** TOP OF LIST **									
TESTIS (TE)	NUMBER EXAMINED:	45	0	0	5	0	0	0	0
	NOT REMARKABLE:	44	0	0	4	0	0	0	0
--DEGENERATION, UNILATERAL		1	0	0	0	0	0	0	0
--DEGENERATION, BILATERAL		0	0	0	1	0	0	0	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	45	0	0	5	39	2	0	0
	NOT REMARKABLE:	9	0	0	4	16	0	0	0
--MINERALIZATION, FOCAL, THALAMUS		35	0	0	1	23	1	0	0
--DILATED VENTRICLE(S)		1	0	0	0	0	0	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
--VENTRAL COMPRESSION		0	0	0	0	1	1	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	38	0	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	38	0	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	38	0	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
PITUITARY (PI)	NUMBER EXAMINED:	42	0	0	3	38	2	2	0
	NOT REMARKABLE:	38	0	0	3	29	0	0	0
--B-ADENOMA		0	0	0	0	4	2	0	0
--CYST(S)		3	0	0	0	0	0	0	0
--HYPERPLASIA, FOCAL		1	0	0	0	4	0	1	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
** FROM PREVIOUS PAGE **									
PITUITARY (PI)	NUMBER EXAMINED:	42	0	0	3	38	2	2	0
	NOT REMARKABLE:	38	0	0	3	29	0	0	0
--HEMATOCYST		0	0	0	0	1	0	0	0
--ANGIECTASIS		0	0	0	0	0	0	1	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	1	0	0	0	1	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	1	0	0	0
--B-ADENOMA		5	0	0	0	1	0	0	0
--HYPERPLASIA, SUBCAPSULAR CELL		41	0	0	3	38	0	0	0
--DEGENERATION/NECROSIS, CORTICOMEDULLARY JUNCTION		11	0	0	5	35	0	0	0
--CONGESTION/HEMORRHAGE, CORTICOMEDULLARY JUNCTION		3	0	0	2	14	0	0	0
--HYPERTROPHY, FOCAL		14	0	0	0	1	0	0	0
--HYPERPLASIA, FOCAL		2	0	0	0	0	0	0	0
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
THYROID (TY)	NUMBER EXAMINED:	44	0	0	5	38	0	0	0
	NOT REMARKABLE:	41	0	0	4	35	0	0	0
--B-FOLLICULAR CELL ADENOMA		2	0	0	1	2	0	0	0
--M-FOLLICULAR CELL CARCINOMA		0	0	0	0	1	0	0	0
--CYSTIC FOLLICLE(S)		1	0	0	0	0	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	35	0	0	5	34	0	0	0
	NOT REMARKABLE:	35	0	0	5	33	0	0	0
--HYPERPLASIA, FOCAL		0	0	0	0	1	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;W_KS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

--- NUMBER-OF-ANIMALS-AFFECTED ---

ORGAN AND FINDING DESCRIPTION		SEX:	MALE				FEMALE			
		GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		NUMBER:	45	43	41	5	39	37	42	0
ESOPHAGUS (ES)	NUMBER EXAMINED:		45	0	0	5	38	0	0	0
	NOT REMARKABLE:		45	0	0	5	37	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)			0	0	0	0	1	0	0	0
TRACHEA (TR)	NUMBER EXAMINED:		45	0	0	5	38	0	0	0
	NOT REMARKABLE:		45	0	0	5	38	0	0	0
LUNG (LU)	NUMBER EXAMINED:		45	1	3	5	39	2	3	0
	NOT REMARKABLE:		3	0	0	1	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)			1	0	0	0	1	0	1	0
--B-ALVEOLAR/BRONCHIOLAR ADENOMA			2	0	0	0	0	0	0	0
--M-ALVEOLAR/BRONCHIOLAR CARCINOMA			2	1	2	0	3	1	1	0
--N-HEPATOCELLULAR CARCINOMA, METASTATIC			1	0	0	2	0	0	0	0
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID			39	1	2	2	37	1	1	0
--CONGESTION/HEMORRHAGE, AGONAL			2	0	1	0	1	0	0	0
--INFLAMMATION, CHRONIC, FOCAL			1	0	0	0	2	0	1	0
--INFLAMMATION, CHRONIC, PLEURA			1	0	0	0	1	0	0	0
--HYPERPLASIA, ALVEOLAR CELL			2	0	0	0	1	0	0	0
--PIGMENT LADEN MACROPHAGES			1	0	0	0	0	0	0	0
--ALVEOLAR HISTIOCYTOSIS			1	1	0	0	0	0	2	0
HEART (HT)	NUMBER EXAMINED:		45	0	0	5	39	0	0	0
	NOT REMARKABLE:		44	0	0	5	38	0	0	0
--DEGENERATION, MYOCARDIUM			1	0	0	0	1	0	0	0
LIVER (LI)	NUMBER EXAMINED:		45	43	41	5	39	37	42	0
	NOT REMARKABLE:		23	14	0	0	1	4	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)			2	1	0	0	3	7	0	0
--B-HEPATOCELLULAR ADENOMA			4	7	14	0	3	4	14	0
--M-HEPATOCELLULAR CARCINOMA			7	3	22	5	1	1	23	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
** FROM PREVIOUS PAGE **									
LIVER (LI)	NUMBER EXAMINED:	45	43	41	5	39	37	42	0
	NOT REMARKABLE:	23	14	0	0	1	4	2	0
--M-HEMANGIOSARCOMA		1	0	0	0	0	0	0	0
--HEPATOCYTOMEGALY, CENTRILOBULAR		0	0	25	0	0	0	1	0
--INFLAMMATION, CHRONIC, FOCAL		7	17	5	0	36	25	24	0
--NECROSIS, FOCAL		0	0	1	0	0	0	0	0
--LIPOIDOSIS, NONZONAL		1	4	0	0	0	0	0	0
--CELLULAR ALTERATION, CLEAR		1	2	0	0	1	0	0	0
--CELLULAR ALTERATION, GROUND GLASS		3	1	0	0	0	0	0	0
--CELLULAR ALTERATION, BASOPHILIC		0	1	0	0	0	0	1	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		1	0	0	0	0	1	0	0
--INFARCTED NODULE		0	0	0	0	0	0	1	0
--BILE DUCT, CYST		0	1	0	0	0	0	0	0
GALLBLADDER (GB)	NUMBER EXAMINED:	41	0	0	3	37	0	0	0
	NOT REMARKABLE:	41	0	0	3	37	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	45	10	8	5	39	1	7	0
	NOT REMARKABLE:	0	0	0	1	29	0	3	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	1	0	0
--B-BENIGN TUBULE CELL ADENOMA		1	0	0	0	0	0	0	0
--NEPHROPATHY, CHRONIC PROGRESSIVE		42	9	6	1	7	0	3	0
--TUBULE, MINERALIZATION		42	9	7	1	1	0	0	0
--TUBULE CELLS, PROTEIN RESORPTION DROPLETS		1	0	0	0	0	0	0	0
--HYPERPLASIA, TUBULAR EPITHELIUM		0	0	0	1	0	0	0	0
--PYELONEPHRITIS		1	0	1	0	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	1	0	0	0
--PIGMENT, PROXIMAL TUBULES		0	0	0	1	0	0	0	0
--PELVIS, DILATATION		1	0	0	0	0	0	0	0
--CYST		4	1	0	2	0	0	0	0
--METAPLASIA, OSSEOUS		1	0	0	0	0	0	0	0
--HYDRONEPHROSIS, UNILATERAL		0	0	0	0	0	0	1	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	45	43	41	5	39	37	42	0
SPLEEN (SP)	NUMBER EXAMINED:	45	2	2	5	39	9	9	0
	NOT REMARKABLE:	40	0	0	4	33	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	1	0	4	5	4	0
--M-HEMANGIOSARCOMA		1	1	0	1	0	0	3	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		1	0	1	0	0	2	0	0
--PIGMENT, INCREASED		0	0	0	0	1	0	1	0
--CONGESTION/HEMORRHAGE		0	0	1	0	0	0	0	0
--HYPERPLASIA, LYMPHOID		1	0	0	0	2	2	2	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	44	0	1	5	39	0	2	0
	NOT REMARKABLE:	44	0	1	5	39	0	1	0
--B-SQUAMOUS CELL PAPILLOMA		0	0	0	0	0	0	1	0
STOMACH, GL (ST)	NUMBER EXAMINED:	44	0	2	5	39	2	1	0
	NOT REMARKABLE:	44	0	1	4	37	1	1	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--ULCER		0	0	0	0	0	1	0	0
--EROSION		0	0	1	1	0	0	0	0
--MINERALIZATION, FOCAL, MUCOSA		0	0	0	0	1	0	0	0
DUODENUM (DU)	NUMBER EXAMINED:	45	1	0	5	39	1	1	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	0	1	1	0
--M-CARCINOMA		0	1	0	0	0	0	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	44	0	0	5	39	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	0	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
ILEUM (IL)	NUMBER EXAMINED:	45	0	0	5	38	0	0	0
	NOT REMARKABLE:	45	0	0	5	38	0	0	0
PANCREAS (PA)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	42	0	0	5	38	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	1	0	0	0
--B-ISLET CELL ADENOMA		1	0	0	0	0	0	0	0
--ATROPHY, ACINAR CELL		1	0	0	0	0	0	0	0
CECUM (CE)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
COLON (CO)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
RECTUM (RE)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	45	4	5	5	39	8	4	0
	NOT REMARKABLE:	26	0	0	3	34	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		3	3	3	0	2	7	2	0
--CONGESTION/HEMORRHAGE		16	1	2	2	2	0	1	0
--HYPERPLASIA, LYMPHOID		0	0	0	0	1	0	1	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	45	0	0	5	0	0	0	0
	NOT REMARKABLE:	45	0	0	5	0	0	0	0

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
PROSTATE (PR)	NUMBER EXAMINED:	45	0	0	5	0	0	0	0
	NOT REMARKABLE:	45	0	0	4	0	0	0	0
--ATROPHY		0	0	0	1	0	0	0	0
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	45	4	6	5	0	0	0	0
	NOT REMARKABLE:	38	3	4	3	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	0	0	0	0
--DECREASED SECRETION, BILATERAL		0	0	0	2	0	0	0	0
--DISTENDED		6	1	2	0	0	0	0	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	39	5	16	0
	NOT REMARKABLE:	0	0	0	0	11	1	1	0
--ATROPHY		0	0	0	0	17	0	1	0
--BURSA, CYST		0	0	0	0	2	0	4	0
--CYST(S)		0	0	0	0	14	4	11	0
--HEMATOCYST		0	0	0	0	10	2	4	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	39	31	35	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--B-ENDOMETRIAL STROMAL POLYP		0	0	0	0	2	0	0	0
--M-LEIOMYOSARCOMA		0	0	0	0	1	0	0	0
--HYPERPLASIA, CYSTIC ENDOMETRIAL		0	0	0	0	39	30	34	0
--DILATATION		0	0	0	0	3	5	8	0
--AMYLOIDOSIS		0	0	0	0	0	1	0	0
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	36	1	1	0
	NOT REMARKABLE:	0	0	0	0	34	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--M-SARCOMA		0	0	0	0	0	1	0	0
--M-HEMANGIOSARCOMA		0	0	0	0	0	0	1	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
** FROM PREVIOUS PAGE **									
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	36	1	1	0
	NOT REMARKABLE:	0	0	0	0	34	0	0	0
--ENDOMETRIAL CYST(S)		0	0	0	0	1	0	1	0
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	39	0	0	0
	NOT REMARKABLE:	0	0	0	0	39	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	44	1	0	5	39	0	0	0
	NOT REMARKABLE:	44	1	0	5	39	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	37	0	0	4	34	2	0	0
	NOT REMARKABLE:	36	0	0	4	31	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	3	2	0	0
EYE (EY)	NUMBER EXAMINED:	45	0	0	5	39	1	0	0
	NOT REMARKABLE:	45	0	0	5	38	1	0	0
--CATARACT		0	0	0	0	1	0	0	0
--PHTHISIS		0	0	0	0	1	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	45	0	1	5	39	2	0	0
	NOT REMARKABLE:	41	0	0	4	33	0	0	0
--B-ADENOMA		4	0	1	1	6	2	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
THYMUS (TH)	NUMBER EXAMINED:	31	0	0	4	36	2	0	0
	NOT REMARKABLE:	30	0	0	4	35	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	1	2	0	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	37	0	0	0
--DEGENERATION		0	0	0	0	2	0	0	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	43	0	0	5	36	0	0	0
	NOT REMARKABLE:	14	0	0	2	3	0	0	0
--DEGENERATION		29	0	0	3	33	0	0	0
SKIN (SK)	NUMBER EXAMINED:	45	0	0	5	39	0	0	0
	NOT REMARKABLE:	45	0	0	5	39	0	0	0
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	36	0	1	0
	NOT REMARKABLE:	0	0	0	0	30	0	0	0
--M-CARCINOMA		0	0	0	0	0	0	1	0
--DILATATION, DUCT(S)		0	0	0	0	1	0	0	0
--LACTATION		0	0	0	0	4	0	0	0
--HYPERPLASIA, LOBULAR		0	0	0	0	2	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	44	0	0	5	39	0	0	0
	NOT REMARKABLE:	42	0	0	5	17	0	0	0
--HYPERPLASIA, GRANULOCYTIC		1	0	0	0	0	0	0	0
--FIBROOSSEOUS CHANGE		1	0	0	0	22	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
BONE, [illegible]UR (FE)	NUMBER EXAMINED:	44	0	0	5	39	0	0	0
	NOT REMARKABLE:	44	0	0	5	36	0	0	0
--FIBROUS OSTEODYSTROPHY		0	0	0	0	3	0	0	0
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	45	3	4	5	39	10	7	0
	NOT REMARKABLE:	41	0	0	5	34	0	0	0
--M-MALIGNANT LYMPHOMA, LYMPHOCYTIC		1	2	1	0	3	2	2	0
--M-MALIGNANT LYMPHOMA, HISTIOCYTIC		2	1	0	0	0	7	4	0
--M-MALIGNANT LYMPHOMA, UNDIFFERENTIATED		1	0	3	0	2	1	1	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	12	9	13	2	12	8	15	0
	NOT REMARKABLE:	9	8	11	2	12	7	15	0
--B-SEBACEOUS ADENOMA		1	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC		1	1	0	0	0	0	0	0
--ULCER, PREPUCE		1	0	0	0	0	0	0	0
--ULCER, SHOULDER		0	0	1	0	0	0	0	0
--ULCER, EAR		0	0	1	0	0	0	0	0
--ULCER, NECK		1	0	0	0	0	0	0	0
--ULCER FOOT		0	0	0	0	0	1	0	0
--ESCHAR, EAR		0	0	1	0	0	0	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	0	0	1	1	0	0	1	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	0	1	0	0	1	0
--M-HEMANGIOSARCOMA		0	0	1	0	0	0	1	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	1	5	3	0	0	0	0	0
	NOT REMARKABLE:	0	0	1	0	0	0	0	0
--CYSTIC DUCT(S)		1	1	2	0	0	0	0	0
--ABSCESS		0	4	0	0	0	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		45	43	41	5	39	37	42	0
LN, OTHER(S) (LN)	NUMBER EXAMINED:	2	0	1	0	0	6	2	0
	NOT REMARKABLE:	0	0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	1	0	0	4	2	0
--HYPERPLASIA, LYMPHOID		1	0	0	0	0	1	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	2	0	0	0	0	0	0	0
	NOT REMARKABLE:	1	0	0	0	0	0	0	0
--FAT NECROSIS		1	0	0	0	0	0	0	0
PENIS (PE)	NUMBER EXAMINED:	0	1	1	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--SEMINAL PLUG		0	1	0	0	0	0	0	0
--ULCER, PREPUCE		0	0	1	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	1	0	0	0	0	0	0	0

** END OF LIST **

HAZLETON
WASHINGTON
9200 LEESBURG PIKE
VIENNA, VA 22182-1699

Telefax: (703) 759-6947
Confirm: (703) 893-5400 x 5264

FACSIMILE TRANSMISSION

TO: Chemical Manufacturers Association

DATE: July 28, 1993

ATTN: Dr. Carol Stack

cc: D. Brusick
R. Squibb
C. Murphy
R. Cardy

FROM: Dr. Michael R. Moore

TOTAL NUMBER OF PAGES BEING TRANSMITTED: 15

SUBJECT: 104-Week Dietary Carcinogenicity Study with 1,2,4-Trichlorobenzene in Mice (HWA Project No. 2603-102; CMA Reference No. CB-28.0-ONC-HAZ)

Attached is UNAUDITED DRAFT HISTOPATHOLOGY SUMMARY INCIDENCE TABLE FOR All DEATHS (Death = All); or rather a combined total incidence for all animals in each group (unscheduled deaths plus those killed at study termination).

Perhaps the attached table illustrates the questions that may arise concerning whether findings for the adrenal, testes, and seminal vesicles in the high-dose mice are primary or secondary responses to the test material.

With best regards,

Mike

Michael R. Moore, Ph.D., D.A.B.T.
Associate Director, Toxicology

PSO/2603-102
TOX
McKay
Proj. Mgmt.

HAZLETON WASHINGTON, INC.

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

PRINTED: 13-JUL-93
PAGE: 1

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** TOP OF LIST **									
TESTIS (TE)	NUMBER EXAMINED:	50	7	9	50	0	0	0	0
	NOT REMARKABLE:	49	7	7	40	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--DEGENERATION, UNILATERAL		1	0	1	1	0	0	0	0
--DEGENERATION, BILATERAL		0	0	0	9	0	0	0	0
BRAIN W/STEM (BR)	NUMBER EXAMINED:	50	7	9	49	50	14	8	50
	NOT REMARKABLE:	13	5	3	33	23	9	5	37
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--MINERALIZATION, FOCAL, THALAMUS		36	2	5	16	27	3	2	13
--DILATED VENTRICLE(S)		1	0	0	0	0	0	0	0
--HEMORRHAGE, FOCAL		0	0	0	0	0	0	1	0
--MALACIA, FOCAL		0	0	0	0	0	1	0	0
--GLIOSIS, FOCAL		0	0	0	0	0	1	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
--VENTRAL COMPRESSION		0	0	0	0	1	1	0	0
CORD, CERVICAL (CS)	NUMBER EXAMINED:	50	7	9	49	50	12	8	50
	NOT REMARKABLE:	50	7	8	49	49	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
CORD, THORACIC (TC)	NUMBER EXAMINED:	50	7	9	49	50	12	8	50
	NOT REMARKABLE:	50	7	8	49	49	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
CORD, LUMBAR (LC)	NUMBER EXAMINED:	50	7	8	49	50	12	8	50
	NOT REMARKABLE:	50	7	7	49	49	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
CORD, LUMBAR (LC)	NUMBER EXAMINED:	50	7	8	49	50	12	8	50
	NOT REMARKABLE:	50	7	7	49	49	12	8	50
--LYMPHOCYTIC INFILTRATE, MENINGES		0	0	0	0	1	0	0	0
PITUITARY (PI)	NUMBER EXAMINED:	47	5	7	41	48	14	10	46
	NOT REMARKABLE:	43	5	7	41	38	12	8	46
--B-ADENOMA		0	0	0	0	5	2	0	0
--CYST(S)		3	0	0	0	0	0	0	0
--HYPERPLASIA, FOCAL		1	0	0	0	4	0	1	0
--HEMATOCYST		0	0	0	0	1	0	0	0
--ANGIECTASIS		0	0	0	0	0	0	1	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	49	7	9	49	50	13	8	50
	NOT REMARKABLE:	1	0	0	7	1	0	0	1
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	3	0	2	1	1	0
--B-ADENOMA		5	1	0	0	1	0	0	0
--HYPERPLASIA, SUBCAPSULAR CELL		44	7	8	22	49	13	7	44
--DEGENERATION/NECROSIS, CORTICOMEDULLARY JUNCTION		13	0	1	25	45	9	4	27
--CONGESTION/HEMORRHAGE, CORTICOMEDULLARY JUNCTION		5	0	0	22	16	2	4	25
--NECROSIS, UNILATERAL		0	0	0	1	0	0	0	0
--NECROSIS, BILATERAL		0	0	0	0	0	1	0	0
--HYPERTROPHY, FOCAL		14	1	0	0	1	0	0	0
--HYPERPLASIA, FOCAL		2	0	0	0	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
ADRENAL, MEDULLA (AM)	NUMBER EXAMINED:	49	7	9	47	50	13	8	50
	NOT REMARKABLE:	49	7	9	47	50	13	8	50

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
THYROID (TY)	NUMBER EXAMINED:	48	7	8	48	49	13	8	50
	NOT REMARKABLE:	45	7	8	46	46	13	8	49
--B-FOLLICULAR CELL ADENOMA		2	0	0	1	2	0	0	0
--M-FOLLICULAR CELL CARCINOMA		0	0	0	0	1	0	0	0
--M-"C" CELL CARCINOMA		0	0	0	1	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--CYSTIC FOLLICLE(S)		1	0	0	0	0	0	0	0
PARATHYROID (PT)	NUMBER EXAMINED:	38	7	9	40	44	10	8	46
	NOT REMARKABLE:	38	7	8	40	43	9	7	45
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--CYST(S)		0	0	1	0	0	1	1	0
--HYPERPLASIA, FOCAL		0	0	0	0	1	0	0	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	50	7	9	50	49	12	8	50
	NOT REMARKABLE:	50	7	9	50	47	12	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	2	0	0	0
TRACHEA (TR)	NUMBER EXAMINED:	50	7	9	49	49	12	8	50
	NOT REMARKABLE:	50	7	9	49	49	12	8	50
LUNG (LU)	NUMBER EXAMINED:	50	8	12	50	50	15	11	50
	NOT REMARKABLE:	4	2	2	13	0	1	0	9
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	2	0	5	4	3	0
--B-ALVEOLAR/BRONCHIOLAR ADENOMA		3	0	1	2	0	0	0	1
--M-ALVEOLAR/BRONCHIOLAR CARCINOMA		3	1	3	0	3	1	1	0
--N-HEPATOCELLULAR CARCINOMA, METASTATIC		1	0	0	11	0	0	0	8
--N-KUPFFER CELL SARCOMA		0	0	0	1	0	0	1	0
--N-SARCOMA, METASTATIC, PRIMARY UNKNOWN		0	0	0	1	0	0	0	0
--N-FIBROSARCOMA, METASTATIC		0	0	1	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
LUNG (LU)	NUMBER EXAMINED:	50	8	12	50	50	15	11	50
	NOT REMARKABLE:	4	2	2	13	0	1	0	9
--PERIBRONCHIAL/PERIVASCULAR, INFILTRATION, LYMPHOID		40	5	6	17	44	9	7	23
--CONGESTION/HEMORRHAGE, AGONAL		3	1	2	22	3	1	2	18
--FOAM-CELL FOCUS(I)		1	0	0	2	0	0	0	4
--INFLAMMATION, CHRONIC, FOCAL		1	0	1	1	3	0	2	1
--INFLAMMATION, SUBACUTE, TUMOR ASSOCIATED		1	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC, PLEURA		1	0	0	0	1	0	0	0
--HYPERPLASIA, HILAR LYMPH NODE		0	0	0	0	0	0	0	1
--HYPERPLASIA, ALVEOLAR CELL		2	0	0	0	1	0	0	0
--PIGMENT LADEN MACROPHAGES		1	0	0	0	0	0	0	0
--ALVEOLAR HISTIOCYTOSIS		1	1	0	0	0	0	2	0
HEART (HT)	NUMBER EXAMINED:	50	7	9	50	50	13	8	50
	NOT REMARKABLE:	49	7	8	47	48	10	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--FIBROSIS, MYOCARDIUM		0	0	0	2	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--DEGENERATION, MYOCARDIUM		1	0	0	1	1	2	1	1
--INFLAMMATION, CHRONIC, FOCAL		0	0	0	0	0	1	0	0
LIVER (LI)	NUMBER EXAMINED:	49	50	50	50	50	50	50	50
	NOT REMARKABLE:	25	16	0	0	7	9	2	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	3	4	0	6	12	3	0
--B-HEPATOCELLULAR ADENOMA		4	7	16	2	3	4	16	8
--M-HEPATOCELLULAR CARCINOMA		8	5	27	50	1	1	28	46
--M-KUPFFER CELL SARCOMA		0	0	0	1	0	0	1	0
--M-HEMANGIOSARCOMA		2	0	0	0	1	0	0	0
--HEPATOCYTOMEGALY, CENTRILOBULAR		0	0	27	20	0	0	1	8
--INFLAMMATION, CHRONIC, FOCAL		7	18	7	1	36	25	25	2
--FIBROSIS, PORTAL		0	0	0	2	0	0	0	0
--INFLAMMATION, CHRONIC ACTIVE, PORTAL		0	0	0	4	0	0	1	2

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
LIVER (LI)	NUMBER EXAMINED:	49	50	50	50	50	50	50	50
	NOT REMARKABLE:	25	16	0	0	7	9	2	0
--NECROSIS, FOCAL		0	0	3	3	0	1	2	7
--NECROSIS, SINGLE CELL		0	0	0	1	0	0	0	0
--HYPERPLASIA, OVAL CELL		0	0	0	1	0	0	0	0
--HYPERPLASIA, REGENERATIVE		0	0	0	2	0	0	0	0
--HYPERPLASIA, KUPFFER CELL, FOCAL		0	0	0	0	1	0	0	0
--LIPOIDOSIS, NONZONAL		1	4	0	3	0	0	0	0
--LIPOIDOSIS, FOCAL		0	0	0	0	0	1	0	0
--CELLULAR ALTERATION, EOSINOPHILIC		0	0	0	0	0	0	1	0
--CELLULAR ALTERATION, CLEAR		1	2	0	0	1	0	0	0
--CELLULAR ALTERATION, GROUND GLASS		3	1	0	0	0	0	0	0
--CELLULAR ALTERATION, BASOPHILIC		0	1	0	0	0	0	1	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		1	0	0	0	0	2	0	0
--HEMATOCYST, TUMOR ASSOCIATED		0	0	0	0	0	0	1	8
--INFARCTED NODULE		0	0	0	2	1	0	1	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--BILE DUCT, CYST		0	1	0	0	0	0	0	0
--DEGENERATION, CYSTIC		0	1	0	0	0	0	0	0
GALLBLADDER (GB)	NUMBER EXAMINED:	41	3	4	9	41	7	2	12
	NOT REMARKABLE:	41	3	4	8	41	7	2	12
--INSPISSATED, MINERALIZED BILE		0	0	0	1	0	0	0	0
KIDNEY (KD)	NUMBER EXAMINED:	49	17	17	49	50	14	15	48
	NOT REMARKABLE:	1	1	1	30	36	9	6	33
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	2	3	1	0
--B-BENIGN TUBULE CELL ADENOMA		1	0	0	0	0	0	0	0
--M-MALIGNANT TUBULE CELL CARCINOMA		0	0	0	0	1	0	0	0
--NEPHROPATHY, CHRONIC PROGRESSIVE		42	11	10	5	7	2	6	6
--TUBULE, MINERALIZATION		45	12	9	9	2	0	2	5
--TUBULE CELLS, PROTEIN RESORPTION DROPLETS		1	1	1	0	1	0	0	0

** CONTINUED ON NEXT PAGE **

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
KIDNEY (KD)	NUMBER EXAMINED:	49	17	17	49	50	14	15	48
	NOT REMARKABLE:	1	1	1	30	36	9	6	33
--HYPERPLASIA, TUBULAR EPITHELIUM		0	0	0	2	0	0	0	0
--PYELONEPHRITIS		1	2	2	1	0	0	0	0
--AMYLOIDOSIS		0	0	0	1	2	0	0	1
--PIGMENT, PROXIMAL TUBULES		0	0	0	3	0	0	1	4
--PELVIS, DILATATION		1	0	0	0	0	0	0	1
--PELVIS, CALCULUS		0	0	0	0	0	0	1	0
--CYST		5	1	1	3	0	0	0	0
--METAPLASIA, OSSEOUS		1	0	0	0	0	0	0	1
--MINERALIZATION, CAPSULE		0	0	0	1	0	0	0	0
--HYDRONEPHROSIS, UNILATERAL		0	0	0	0	0	0	1	0
--MAST CELL INFILTRATE		0	1	0	0	0	0	0	0
SPLEEN (SP)	NUMBER EXAMINED:	49	9	11	48	50	22	16	48
	NOT REMARKABLE:	42	3	5	46	38	6	5	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	3	4	0	6	11	6	0
--M-HEMANGIOSARCOMA		2	1	0	1	0	0	3	0
--EXTRAMEDULLARY HEMATOPOIESIS, INCREASED		1	1	2	1	3	3	0	0
--PIGMENT, INCREASED		0	1	0	0	2	0	1	0
--CONGESTION/HEMORRHAGE		1	0	1	0	0	0	0	0
--HYPERPLASIA, LYMPHOID		1	0	0	0	3	2	2	0
STOMACH, NONGL (SU)	NUMBER EXAMINED:	47	7	9	48	47	11	9	49
	NOT REMARKABLE:	47	6	7	47	46	10	8	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--B-SQUAMOUS CELL PAPILLOMA		0	0	0	0	0	0	1	0
--HYPERKERATOSIS		0	0	1	0	0	1	0	1
--HEMORRHAGE, MUSCULARIS		0	0	0	1	0	0	0	0
--MAST CELL INFILTRATE		0	1	0	0	0	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
STOMACH, GL (ST)	NUMBER EXAMINED:	47	6	10	47	47	13	8	49
	NOT REMARKABLE:	47	5	6	45	42	11	8	47
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	4	0	0	0
--ULCER		0	0	1	1	1	1	0	1
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
--EROSION		0	1	1	1	1	1	0	0
--MINERALIZATION, FOCAL, MUCOSA		0	0	0	0	1	0	0	0
DUODENUM (DU)	NUMBER EXAMINED:	47	6	5	25	45	7	6	28
	NOT REMARKABLE:	47	5	5	25	43	6	5	27
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	1	1	0
--M-CARCINOMA		0	1	0	0	1	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
JEJUNUM (JE)	NUMBER EXAMINED:	47	6	5	18	44	6	4	22
	NOT REMARKABLE:	46	6	5	18	44	6	4	21
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	0	0	0	0	0	0
--AMYLOIDOSIS		0	0	0	0	0	0	0	1
ILEUM (IL)	NUMBER EXAMINED:	46	6	5	22	43	5	5	20
	NOT REMARKABLE:	46	6	5	22	43	5	5	20
PANCREAS (PA)	NUMBER EXAMINED:	49	7	8	43	49	9	7	48
	NOT REMARKABLE:	45	7	5	43	45	8	7	47
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	3	0	3	1	0	0
--B-ISLET CELL ADENOMA		1	0	0	0	0	0	0	0
--CYTOPLASMIC CHANGE, EOSINOPHILIC		1	0	0	0	0	0	0	0
--CYSTIC DUCT(S)		0	0	0	0	1	0	0	1
--ATROPHY, ACINAR CELL		1	0	0	0	0	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
CECUM (CE)	NUMBER EXAMINED:	48	4	7	29	44	6	5	25
	NOT REMARKABLE:	48	4	5	29	43	6	5	25
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	1	0	0	0
COLON (CO)	NUMBER EXAMINED:	48	5	6	40	48	11	7	42
	NOT REMARKABLE:	48	5	6	40	48	11	7	42
RECTUM (RE)	NUMBER EXAMINED:	49	6	8	40	48	10	7	43
	NOT REMARKABLE:	49	5	8	40	48	10	7	43
--BLOOD FILLED		0	1	0	0	0	0	0	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	48	9	13	36	47	17	2	45
	NOT REMARKABLE:	28	3	2	24	39	5	4	31
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		4	4	7	0	5	12	3	0
--M-HEMANGIOSARCOMA		0	0	0	2	0	0	0	1
--CONGESTION/HEMORRHAGE		16	2	4	10	3	0	4	13
--HYPERPLASIA, LYMPHOID		0	0	0	0	1	0	1	0
EPIDIDYMIS (EP)	NUMBER EXAMINED:	49	7	9	49	0	0	0	0
	NOT REMARKABLE:	49	7	6	48	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	0	0	0	0
--M-SCHWANNOMA		0	0	1	0	0	0	0	0
--HYPOSPERMIA		0	0	0	1	0	0	0	0
PROSTATE (PR)	NUMBER EXAMINED:	50	7	9	43	0	0	0	0
	NOT REMARKABLE:	49	7	6	41	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	2	0	0	0	0	0
--ATROPHY		0	0	0	2	0	0	0	0
--INFLAMMATION, SUBACUTE		0	0	1	0	0	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
SEMINAL VESICLE (SV)	NUMBER EXAMINED:	48	10	15	45	0	0	0	0
	NOT REMARKABLE:	41	9	10	21	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		1	0	2	0	0	0	0	0
--DECREASED SECRETION, BILATERAL		0	0	0	24	0	0	0	0
--DISTENDED		6	1	3	0	0	0	0	0
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	50	17	24	45
	NOT REMARKABLE:	0	0	0	0	13	6	4	13
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	2	1	1	0
--B-TERATOMA		0	0	0	0	0	1	0	0
--M-MALIGNANT GRANULOSA/THECA CELL TUMOR		0	0	0	0	0	0	1	1
--M-HEMANGIOSARCOMA		0	0	0	0	0	1	0	0
--N-HEPATOCELLULAR CARCINOMA, METASTATIC		0	0	0	0	0	0	0	1
--ATROPHY		0	0	0	0	22	2	4	28
--BURSA, CYST		0	0	0	0	2	0	4	1
--CYST(S)		0	0	0	0	17	4	13	4
--HEMATOCYST		0	0	0	0	12	5	4	0
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	48	43	43	49
	NOT REMARKABLE:	0	0	0	0	1	1	2	41
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--B-ENDOMETRIAL STROMAL POLYP		0	0	0	0	2	0	0	0
--B-HEMANGIOMA		0	0	0	0	0	1	0	0
--M-LEIOMYOSARCOMA		0	0	0	0	1	1	0	0
--HYPERPLASIA, CYSTIC ENDOMETRIAL		0	0	0	0	47	41	40	3
--DILATATION		0	0	0	0	3	5	8	4
--AMYLOIDOSIS		0	0	0	0	0	1	0	1
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	47	12	6	48
	NOT REMARKABLE:	0	0	0	0	42	11	5	46
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	4	0	0	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
UTERUS, CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	47	12	6	48
	NOT REMARKABLE:	0	0	0	0	42	11	5	46
--M-SARCOMA		0	0	0	0	0	1	0	0
--M-HEMANGIOSARCOMA		0	0	0	0	0	0	1	0
--ENDOMETRIAL CYST(S)		0	0	0	0	1	0	1	2
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	50	11	7	48
	NOT REMARKABLE:	0	0	0	0	49	11	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	48	8	9	37	48	9	6	44
	NOT REMARKABLE:	48	7	6	37	46	9	6	42
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	2	0	2	0	0	0
--B-SCHWANNOMA		0	0	0	0	0	0	0	2
--INFLAMMATION, SUPPURATIVE		0	0	1	0	0	0	0	0
--INFLAMMATION, SUBACUTE		0	1	0	0	0	0	0	0
--HYPERPLASIA, EPITHELIAL		0	1	0	0	0	0	0	0
MAND SALIVARY GL (SG)	NUMBER EXAMINED:	49	7	9	49	50	13	8	50
	NOT REMARKABLE:	49	7	7	49	47	11	8	49
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	2	2	0	0
--AMYLOIDOSIS		0	0	1	0	0	0	0	1
--HYPERPLASIA, LYMPHOID		0	0	0	0	1	0	0	0
LN, MANDIBULAR (MN)	NUMBER EXAMINED:	42	5	7	44	15	14	8	44
	NOT REMARKABLE:	40	4	6	43	40	9	7	43
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	1	0	5	5	1	1
--CONGESTION/HEMORRHAGE		0	0	0	1	0	0	0	0

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
EYE (EY)	NUMBER EXAMINED:	47	7	8	41	48	9	6	39
	NOT REMARKABLE:	47	7	7	40	46	9	6	39
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--CATARACT		0	0	0	1	1	0	0	0
--PHTHISIS		0	0	0	0	1	0	0	0
HARDERIAN GLAND (HG)	NUMBER EXAMINED:	50	7	10	48	50	15	8	50
	NOT REMARKABLE:	46	6	7	47	44	11	8	50
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--B-ADENOMA		4	1	1	1	6	2	0	0
--HYPERPLASIA, FOCAL		0	0	1	0	0	1	0	0
--INFLAMMATION, CHRONIC		0	0	0	0	0	1	0	0
THYMUS (TH)	NUMBER EXAMINED:	36	5	9	25	44	11	5	29
	NOT REMARKABLE:	34	5	5	25	41	5	4	29
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	0	4	0	3	6	1	0
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	50	7	9	50	50	13	8	50
	NOT REMARKABLE:	50	7	6	47	47	12	8	49
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--ATROPHY		0	0	0	2	0	0	0	0
--DEGENERATION		0	0	2	1	2	0	0	1
--LYMPHOCYTIC INFILTRATE		0	0	0	0	0	1	0	0
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	48	6	9	50	47	12	8	50
	NOT REMARKABLE:	19	4	3	29	9	6	4	28
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	0	0	0	0
--DEGENERATION		29	2	5	21	38	6	4	22

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
SKIN (SK)	NUMBER EXAMINED:	50	7	9	50	50	12	8	50
	NOT REMARKABLE:	50	6	8	40	49	12	7	41
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	1	0	1	0	0	0
--B-TRICHOEPITHELIOMA		0	0	0	0	0	0	1	0
--EDEMA		0	1	0	10	0	0	0	9
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	44	13	8	37
	NOT REMARKABLE:	0	0	0	0	37	9	7	37
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	1	0	0
--M-CARCINOMA		0	0	0	0	0	0	1	0
--DILATATION, DUCT(S)		0	0	0	0	1	2	0	0
--LACTATION		0	0	0	0	4	1	0	0
--HYPERPLASIA, LOBULAR		0	0	0	0	3	0	0	0
MARROW, FEMUR (FM)	NUMBER EXAMINED:	48	6	9	50	49	13	7	49
	NOT REMARKABLE:	46	5	7	50	24	10	7	48
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	1	2	0	0	1	0	1
--HYPERPLASIA, GRANULOCYTIC		1	0	0	0	0	1	0	0
--FIBROOSSEOUS CHANGE		1	0	0	0	25	1	0	0
BONE, FEMUR (FE)	NUMBER EXAMINED:	49	7	9	50	50	13	8	50
	NOT REMARKABLE:	49	7	8	50	47	13	8	50
--FIBROUS OSTEODYSTROPHY		0	0	1	0	3	0	0	0
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	50	10	13	50	50	23	15	50
	NOT REMARKABLE:	45	4	5	50	41	7	6	48
--M-MALIGNANT LYMPHOMA, MIXED		0	3	2	0	1	1	0	0
--M-MALIGNANT LYMPHOMA, LYMPHOCYTIC		1	2	2	0	5	4	2	1
--M-MALIGNANT LYMPHOMA, HISTIOCYTIC		2	1	1	0	0	7	5	1
--M-MALIGNANT LYMPHOMA, UNDIFFERENTIATED		1	0	3	0	2	2	2	0

** CONTINUED ON NEXT PAGE **

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
HEMATO NEOPLASIA (HN)	NUMBER EXAMINED:	50	10	13	50	50	23	15	50
	NOT REMARKABLE:	45	4	5	50	41	7	6	48
--M-AUTOLYSED NEOPLASM		1	0	0	0	1	2	0	0
SKIN, OTHER (SS)	NUMBER EXAMINED:	13	11	14	11	14	15	16	4
	NOT REMARKABLE:	10	8	12	7	14	12	16	2
--B-SEBACEOUS ADENOMA		1	0	0	0	0	0	0	0
--EDEMA		0	1	0	3	0	0	0	2
--ATROPHY		0	0	0	2	0	0	0	1
--ACANTHOSIS, FOCAL		0	0	0	0	0	1	0	0
--INFLAMMATION, GRANULOMATOUS, TAIL		0	0	0	1	0	0	0	0
--INFLAMMATION, SUBACUTE, FOOT		0	1	0	0	0	1	0	0
--INFLAMMATION, CHRONIC		1	1	0	0	0	0	0	0
--ULCER, TAIL		0	0	0	1	0	0	0	0
--ULCER, PREPUCE		1	0	0	0	0	0	0	0
--ULCER, SHOULDER		0	0	1	0	0	0	0	0
--ULCER, EAR		0	0	1	0	0	0	0	0
--ULCER, NECK		1	0	0	0	0	0	0	0
--ULCER FOOT		0	0	0	0	0	1	0	0
--ESCHAR, EAR		0	0	1	0	0	0	0	0
SUBCUTANEOUS TIS (SQ)	NUMBER EXAMINED:	1	0	2	1	1	1	2	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--M-FIBROSARCOMA		0	0	1	1	1	0	2	0
--M-LEIOMYOSARCOMA		1	0	0	0	0	0	0	0
--M-HEMANGIOSARCOMA		0	0	1	0	0	0	1	0
--M-SARCOMA, UNDIFFERENTIATED		0	0	0	0	0	1	0	0
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	1	5	3	2	0	0	0	0
	NOT REMARKABLE:	0	0	1	0	0	0	0	0
--CYSTIC DUCT(S)		1	1	2	2	0	0	0	0

** CONTINUED ON NEXT PAGE **

104-WEEK DIETARY CARCINOGENICITY STUDY WITH
1,2,4-TRICHLOROBENZENE IN MICE
DRAFT HISTOPATHOLOGY INCIDENCE SUMMARY *DRAFT*

STUDY NUMBER: 2603102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=ALL;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		50	50	50	50	50	50	50	50
** FROM PREVIOUS PAGE **									
PREPUTIAL GLAND (PG)	NUMBER EXAMINED:	1	5	3	2	0	0	0	0
	NOT REMARKABLE:	0	0	1	0	0	0	0	0
--ABSCESS		0	4	0	0	0	0	0	0
LN, OTHER(S) (LN)	NUMBER EXAMINED:	3	1	1	0	0	9	3	0
	NOT REMARKABLE:	0	0	0	0	0	1	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		2	1	1	0	0	7	3	0
--HYPERPLASIA, LYMPHOID		1	0	0	0	0	1	0	0
CAVITY, ABDOM (PC)	NUMBER EXAMINED:	2	1	0	1	2	1	0	1
	NOT REMARKABLE:	1	1	0	0	0	0	0	0
--X-HEMATOPOIETIC NEOPLASIA (SEE "HEMATO NEOPLASIA" FOR TYPE)		0	0	0	0	1	0	0	0
--M-MYXOSARCOMA		0	0	0	0	0	1	0	0
--FAT NECROSIS		1	0	0	0	1	0	0	1
--HEMORRHAGE		0	0	0	1	0	0	0	0
PENIS (PE)	NUMBER EXAMINED:	0	2	1	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--INFLAMMATION, NECROTIZING/SUPPURATIVE, PREPUCE		0	1	0	0	0	0	0	0
--INFLAMMATION, NECROTIZING/SUPPURATIVE		0	1	0	0	0	0	0	0
--SEMINAL PLUG		0	1	0	0	0	0	0	0
--ULCER, PREPUCE		0	0	1	0	0	0	0	0
HEAD, CORONAL (HC)	NUMBER EXAMINED:	1	0	0	0	0	0	0	0
	NOT REMARKABLE:	1	0	0	0	0	0	0	0

** END OF LIST **